AbbVie Inc (ABBV)

66.76
1.70 2.60
NYSE : Health Care
Prev Close 65.04
Open 65.45
Day Low/High 65.12 / 65.60
52 Wk Low/High 55.06 / 68.12
Volume 344.61K
Avg Volume 6.12M
Exchange NYSE
Shares Outstanding 1.59B
Market Cap 103.74B
EPS 3.70
P/E Ratio 13.51
Div & Yield 2.56 (3.90%)

Latest News

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures rise modestly Thursday after Donald Trump's tax plan fails to deliver any surprises but instead raises many more questions.

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Nobody shows their hand in negotiations. Why should government? This new tax plan must go to Congress.

Surveying the NASH Drug Landscape

Surveying the NASH Drug Landscape

Biotech investors should keep a close eye on the progress in this huge potential market.

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

EQT Midstream Partners, AbbVie, Blackstone Group: 'Mad Money' Lightning Round

EQT Midstream Partners, AbbVie, Blackstone Group: 'Mad Money' Lightning Round

Jim Cramer is bullish on EQT Midstream Partners, AbbVie, Blackstone Group, and Core Civic.

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.

AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate In Chronic Hepatitis C Patients With Compensated Cirrhosis

AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate In Chronic Hepatitis C Patients With Compensated Cirrhosis

- New data demonstrated high SVR(12) rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C virus (HCV) infection with 12 weeks of treatment(1)

Gilead, Pfizer, AbbVie Win From Lilly's Loss

Gilead, Pfizer, AbbVie Win From Lilly's Loss

The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding In Women With Uterine Fibroids

AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding In Women With Uterine Fibroids

- Elagolix, with or without add-back therapy, showed effective and rapid reduction of heavy menstrual bleeding compared to placebo in women with uterine fibroids

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

Cramer: Stay the Course, but Keep Cash Handy

Cramer: Stay the Course, but Keep Cash Handy

It's pretty normal to have profit-taking after such a strong first quarter.

Dividend Stock Advisor Is Becoming Income Seeker

Subscribers to Dividend Stock Advisor will now receive Income Seeker, our newest premium product.

Must-Own Dividend Dates for April

Mark your calendars!

U.S. FDA Approves Addition Of Moderate To Severe Fingernail Psoriasis Data To AbbVie's HUMIRA® (adalimumab) Prescribing Information

U.S. FDA Approves Addition Of Moderate To Severe Fingernail Psoriasis Data To AbbVie's HUMIRA® (adalimumab) Prescribing Information

- HUMIRA is now the first-and-only biologic treatment with fingernail psoriasis data in its U.S. prescribing information for moderate to severe chronic plaque psoriasis patients

Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug

Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug

Vertex to seek marketing approval for new 'teza/iva' combination therapy for cystic fibrosis patients.

AbbVie And M2Gen Announce New Collaboration For The Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program

AbbVie And M2Gen Announce New Collaboration For The Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program

Avatar Program Offers Potential for Key Discoveries of Nearly 20 Tumor Types and Biomarkers, Increased Patient Recruitment for Clinical Trials Nationwide

The New #141 Most Shorted S&P 500 Component: AbbVie

The New #141 Most Shorted S&P 500 Component: AbbVie

The most recent short interest data has been released for the 03/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Julianne Hough Empowers Women To

Julianne Hough Empowers Women To "Get In The Know" About Endometriosis

- Endometriosis affects an estimated one in 10 women, but diagnosis can take up to six to 10 years

CytomX Soars on Bristol-Myers Partnership

CytomX Soars on Bristol-Myers Partnership

Shares of the biotech, which researches cancer drugs, were up nearly 30% ahead of market's open.

AbbVie Granted Priority Review In Japan For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

AbbVie Granted Priority Review In Japan For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

- Priority review granted in Japan, following EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively

TheStreet Quant Rating: A (Buy)